文献速递系统性红斑狼疮

狼疮肾炎血清可溶性介质特征:组织学表现与治疗反应

Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-12-03

在加速药物伙伴关系狼疮肾炎队列中,268例系统性红斑狼疮患者接受肾活检并检测66种血清可溶性介质。增殖性狼疮肾炎患者具有独特介质谱,LASSO回归识别20种预测介质(AUC 0.82)。增殖性患者3个月时syndecan-1和VCAM-1下降可预测12个月治疗反应(AUC 0.90)。

要点

  • 增殖性狼疮肾炎(III/IV±V型)与非增殖性(I、II或V型)的血清可溶性介质谱不同。
  • 20种介质可预测增殖性狼疮肾炎,AUC为0.82(95%CI 0.81-0.91)。
  • 增殖性患者3个月时syndecan-1和VCAM-1下降联合UPCR下降预测12个月治疗反应,AUC为0.90(95%CI 0.82-0.98)。

核心结论

  • 血清可溶性介质尤其syndecan-1和VCAM-1反映狼疮肾炎组织学活动性,早期下降预测治疗反应,支持其作为无创纵向生物标志物的潜在用途。
  • 狼疮肾炎存在显著异质性,提示生物标志物引导的再分类可能推进精准医学方法。

研究设计与样本

  • 研究纳入加速药物伙伴关系狼疮肾炎队列中268例系统性红斑狼疮患者,均在临床指征下接受肾活检(尿蛋白/肌酐比值≥0.5),并设22例健康对照。
  • 在活检时及活检后3、6、12个月采集血清,用xMAP多重检测定量66种免疫介质,用酶联免疫吸附试验检测TACE。
  • 7种介质因超过95%的值低于检测限被排除分析;采用自举最小绝对收缩和选择算子(LASSO)回归从基线介质中识别增殖性狼疮肾炎(III/IV±V型)预测因子。
  • 采用逻辑回归分析LASSO所选介质3个月变化及UPCR与12个月治疗反应(完全/部分反应 vs 无反应)的关联,并对介质谱进行分子聚类以识别狼疮肾炎亚组。

主要发现

  • 增殖性狼疮肾炎患者(III或IV±V型,n=160)与非增殖性狼疮肾炎患者(I、II或V型,n=96)相比呈现不同的介质谱。
  • LASSO回归识别20种预测增殖性狼疮肾炎的介质,曲线下面积0.82(95%CI 0.81-0.91),包括syndecan-1、肿瘤坏死因子受体I型、肿瘤坏死因子受体II型和血管细胞黏附分子1(VCAM-1)升高,以及CCL3/巨噬细胞炎症蛋白1α、CD40配体和白细胞介素-5降低。
  • 在增殖性狼疮肾炎患者中,3个月时syndecan-1和VCAM-1(与肾内狼疮肾炎活动性和/或慢性化相关的介质)的下降预测12个月治疗反应。
  • 结合这些介质下降和UPCR下降的模型预测增殖性狼疮肾炎治疗反应,曲线下面积0.90(95%CI 0.82-0.98)。
  • 分子聚类揭示四个具有独特可溶性介质特征和临床特征的狼疮肾炎亚组,这些特征无法仅由组织学捕获。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response. METHODS: Patients with systemic lupus erythematosus (SLE) (n = 268) undergoing clinically indicated kidney biopsies (urine protein/creatinine ratio [UPCR] ≥ 0.5) were recruited through the AMP Rheumatoid Arthritis and SLE Network. Serum was collected at biopsy and 3-, 6-, and 12-month postbiopsy, alongside samples from 22 healthy controls. Concentrations of 66 immune mediators were quantified using xMAP multiplex assays, and (TACE) measured by enzyme-linked immunosorbent assay. Seven mediators with >95% values below detection limits were excluded from analyses. Bootstrapped least absolute shrinkage and selection operator (LASSO) regression identified proliferative LN (class III/IV ± V) predictors from baseline mediators. Associations with 12-month treatment response (complete/partial vs no response) were tested using three-month changes in LASSO-selected mediators and UPCR via logistic regression. Molecular clustering of mediator profiles was performed to identify LN subgroups. RESULTS: Proliferative patients with LN (class [III or IV] ± V; n = 160) displayed a distinct mediator profile compared with nonproliferative LN (class I, II, or V; n = 96). LASSO regression identified 20 mediators predictive of proliferative LN (areas under the curve, 0.82; 95% confidence interval [CI], 0.81-0.91), including elevated syndecan-1, tumor necrosis factor receptor type I, tumor necrosis factor receptor type II, and vascular cell adhesion molecule 1 (VCAM-1), as well as decreased CCL3//macrophage inflammatory protein 1α, CD40 ligand, and interleukin-5 levels. Among proliferative patients with LN, 3-month reductions in syndecan-1 and VCAM-1, mediators associated with intrarenal LN activity and/or chronicity, predicted the 12-month treatment response. A model incorporated these reductions and a decline in UPCR-predicted treatment response in proliferative LN (0.90; 95% CI, 0.82-0.98). Molecular clustering revealed four distinct LN subgroups with unique soluble mediator signatures and clinical features not captured by histology alone. CONCLUSION: Serum soluble mediators, particularly syndecan-1 and VCAM-1, reflect LN histologic activity, and early decreases predict treatment response, supporting their potential use as noninvasive longitudinal biomarkers. The substantial heterogeneity within LN highlights the potential for biomarker-guided reclassification to advance precision medicine approaches.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Fava A, Wagner CA, Guthridge CJ, et al. Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment. Arthritis Care Res (Hoboken). 2025. PMID: 41048053. doi:10.1002/acr.25652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。